Phaseline

Companies › Hudson Biotech

Hudson Biotech: clinical trials, targets and expected readouts

7 active drug programs in 8 registered trials: 7 Phase 2, 1 Phase 1; Metabolic and endocrine, Other, Immunology, Gastroenterology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Afamelanotide
Melanocortin receptor 1 agonist
MC1RPhase 2NonSegmental VitiligoFeb 2027
GHK-Cu Gel
Copper(II)-peptide complex with tissue repair activity
–Phase 2Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)Feb 2027
MOTS-c (MDP)
Mitochondrial-derived peptide
–Phase 2PrediabetesFeb 2027
Pentadecapeptide BPC 157
Cytoprotective peptide; mechanisms not fully characterized but proposed to involve angioge
–Phase 2Hamstring Muscle StrainFeb 2027
Tesamorelin
Growth hormone-releasing hormone receptor agonist
GHRHRPhase 2Metabolic Associated Steatotic Liver Disease; HIV-1-infectionFeb 2027
Retatrutide (LY3437943)
Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist
GCGR, GLP1R, GIPRPhase 2ObesityMar 2027
TB-500
Thymosin beta 4 17-23 fragment
TMSB4XPhase 1Atherosclerotic Cardiovascular DiseasesFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07437560AfamelanotidePhase 2NonSegmental VitiligoImmunologyFeb 2027
NCT07505745MOTS-c (MDP)Phase 2PrediabetesMetabolic and endocrineFeb 2027
NCT07437547Pentadecapeptide BPC 157Phase 2Hamstring Muscle StrainOtherFeb 2027
NCT07481734TesamorelinPhase 2Metabolic Associated Steatotic Liver DiseaseGastroenterologyFeb 2027
NCT07487363TB-500Phase 1Atherosclerotic Cardiovascular DiseasesCardiovascularFeb 2027
NCT07437586GHK-Cu GelPhase 2Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)OtherFeb 2027
NCT07467447Retatrutide (LY3437943)Phase 2ObesityMetabolic and endocrineMar 2027
NCT06554717TesamorelinPhase 2HIV-1-infectionInfectious diseaseJun 2028

Targets

MC1R (1) GHRHR (1) TMSB4X (1) GCGR (1) GLP1R (1) GIPR (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche AstraZeneca Hanmi Pharmaceutical Company Hangzhou Sciwind Biosciences Boehringer Ingelheim Altimmune Amgen Regeneron Pharmaceuticals

Companies built like this

Fujian Shengdi Pharmaceutical Shanghai Minwei Biotechnology Beijing QL Biopharmaceutical Daewoong Pharmaceutical Shanghai Argo Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.